Form 4: Immuneering CBO Granted 140,000 Stock Options

Immuneering Corp's Chief Business Officer, Harold Brakewood, was granted 140,000 stock options with an exercise price of $4.91, vesting over four years.

Summary

• Harold Eugene Brakewood, Chief Business Officer of Immuneering Corp (IMRX), was granted 140,000 stock options.
• The stock options have an exercise price of $4.91 per share.
• The transaction date for the option grant was February 3, 2026.
• The options vest in equal monthly installments over a four-year period, commencing on February 1, 2026.
• The options will be fully vested and exercisable on January 1, 2030.
• The expiration date for these stock options is February 3, 2036.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the option grant aligns the Chief Business Officer's financial interests with long-term shareholder value, which is generally favorable for corporate governance and executive motivation.

Positives

• The grant of 140,000 stock options to the Chief Business Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The establishment of a Rule 10b5-1 plan demonstrates a structured approach to insider trading, enhancing transparency and reducing potential for accusations of opportunistic trading.

Future Outlook

The vesting schedule of the stock options, extending to January 1, 2030, indicates a long-term commitment from the Chief Business Officer to the company's future performance and growth.

Industry Context

StockSavvy.ai notes that the grant of stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, designed to attract, retain, and motivate key personnel by linking their financial incentives to the company's stock performance. This aligns with common industry practices for executive equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the Chief Business Officer's financial incentives with the company's stock performance, potentially benefiting shareholders through motivated leadership and long-term value creation.

Next Steps

• The stock options will vest in equal monthly installments over the next four years, commencing February 1, 2026.
• The options will become fully vested and exercisable by January 1, 2030.

Key Dates

Keywords

Immuneering Corp, IMRX, Stock Options, Insider Transaction, Executive Compensation, Form 4, Harold Brakewood, Chief Business Officer, Equity Grant, Rule 10b5-1